78.60 USD
+1.06
1.37%
At close Nov 15, 4:00 PM EST
After hours
77.86
-0.74
0.94%
1 day
1.37%
5 days
-0.23%
1 month
-3.75%
3 months
-2.42%
6 months
5.00%
Year to date
8.47%
1 year
9.15%
5 years
66.74%
10 years
198.07%
 

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 6,990

0
Funds holding %
of 6,704 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

133% more call options, than puts

Call options by funds: $82.9M | Put options by funds: $35.6M

17% more first-time investments, than exits

New positions opened: 95 | Existing positions closed: 81

7% more capital invested

Capital invested by funds: $17.1B [Q2] → $18.4B (+$1.27B) [Q3]

2% more funds holding

Funds holding: 686 [Q2] → 700 (+14) [Q3]

3% less repeat investments, than reductions

Existing positions increased: 255 | Existing positions reduced: 262

2.19% less ownership

Funds ownership: 98.72% [Q2] → 96.52% (-2.19%) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$82
4%
upside
Avg. target
$89
14%
upside
High target
$95
21%
upside

11 analyst ratings

positive
64%
neutral
36%
negative
0%
Raymond James
Andrew Cooper
42% 1-year accuracy
5 / 12 met price target
21%upside
$95
Outperform
Maintained
5 Nov 2024
Mizuho
Anthony Petrone
56% 1-year accuracy
22 / 39 met price target
11%upside
$87
Outperform
Maintained
5 Nov 2024
UBS
Elizabeth Garcia
100% 1-year accuracy
1 / 1 met price target
15%upside
$90
Neutral
Maintained
5 Nov 2024
RBC Capital
Conor McNamara
34% 1-year accuracy
14 / 41 met price target
13%upside
$89
Sector Perform
Maintained
5 Nov 2024
JP Morgan
Casey Woodring
100% 1-year accuracy
1 / 1 met price target
20%upside
$94
Overweight
Maintained
5 Nov 2024

Financial journalist opinion

Based on 19 articles about HOLX published over the past 30 days

Charts implemented using Lightweight Charts™